Montredon Labessonnie, France

Marie Lamothe

USPTO Granted Patents = 12 

 

 

Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Castres, FR (2011 - 2015)
  • Montredon Labessonnie, FR (2019 - 2024)

Company Filing History:


Years Active: 2011-2024

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: Marie Lamothe: Innovator in Cancer Treatment

Introduction

Marie Lamothe is a prominent inventor based in Montredon Labessonnie, France. She has made significant contributions to the field of cancer treatment through her innovative work in antibody-drug conjugates. With a total of 12 patents to her name, Lamothe is recognized for her dedication to advancing medical science.

Latest Patents

Among her latest patents, Lamothe has developed an antibody-drug conjugate for the treatment of cancer. This invention involves an antibody capable of binding to a specific target, which is conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. Additionally, she has created an IGF-1R antibody-drug conjugate, which also targets IGF-1R and employs similar drug derivatives for cancer treatment. These inventions not only showcase her expertise but also hold promise for improving therapeutic outcomes in oncology.

Career Highlights

Marie Lamothe is currently associated with Pierre Fabre Medicament, where she continues to push the boundaries of cancer research. Her work has been instrumental in developing novel therapeutic strategies that leverage the power of targeted drug delivery systems.

Collaborations

Throughout her career, Lamothe has collaborated with notable colleagues, including Michel Perez and Ian Rilatt. These partnerships have fostered a collaborative environment that enhances innovation and accelerates the development of new treatments.

Conclusion

Marie Lamothe's contributions to cancer treatment through her innovative patents exemplify her commitment to improving patient care. Her work in antibody-drug conjugates represents a significant advancement in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…